HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Orphenadrin
Biorphen · C07935 · Disipal · WS 2434 · Orphenadine · Orphenadrin · Orphenedrine · orphenadrine
Identifikatoren & physikalische Daten
| CAS No. | 83-98-7 |
|---|---|
| Summenformel | C18H23NO |
| Durchschnittliche Molmasse | 269,4 g/mol |
| Monoisotopische Masse | 269,17796436 g/mol |
| SMILES | Cc1ccccc1C(OCCN(C)C)c1ccccc1 |
| InChIKey | QVYRGXJJSLMXQH-UHFFFAOYSA-N |
| PubChem CID | 4601 |
| ChEMBL | CHEMBL900 |
| ChEBI | CHEBI:7789 |
| EC No. | 201-509-2 |
| DTXSID | DTXSID3023396 |
| Lokaler Name | Orphenadrin |
Chemische & physikalische Eigenschaften
| XLogP | 3,8 |
|---|---|
| Polarare Oberfläche (TPSA) | 12,5 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 2 |
| Frei drehbare Bindungen | 6 |
| Schwere Atome | 20 |
| Formalladung | 0 |
| Komplexität | 260 |
| Arzneimittel | Pharmaceuticals |
| LogP (Verteilungskoeffizient) | 3.63.77 |
| Color/Form | LIQUID |
| Löslichkeit | Sparingly soluble in waterBITTER TASTE & PRACTICALLY NO ODORWHITE, CRYSTALLINE POWDERSOL IN ACID SOLN /CITRATE/SOL IN WATER, ALCOHOL, CHLOROFORMSPARINGLY SOL IN ACETONE, BENZENEPRACTICALLY INSOL IN ETHER /HYDROCHLORIDE/3.00e-02 g/L1.801mg/L(22.5 ºC) |
| Human Drugs | Breast FeedingLactationMilk, HumanAntiparkinson AgentsCholinergic AntagonistsMuscle Relaxants, CentralParasympatholyticsMuscarinic AntagonistsPharmaceuticals |
| Siedepunkt | 195 °C @ 12 ATMbp12 195° |
| Schmelzpunkt | < 25 °CCRYSTALSMP: 156-157 °CPH OF AQ SOLN ABOUT 5.5 /HYDROCHLORIDE/156 - 157 °C25°C |
| Physical Description | Solid |
| Stability/Shelf Life | SENSITIVE TO LIGHT /CITRATE/ORPHENADRINE BASE PPT FROM AQ ALKALINE SOLN |
| Dissociation Constants | 8.91 |
| Collision Cross Section | 172.5 Ų [M+Na]+ [CCS Type: DTBuffer gas: N2Ionization: ESI+Dataset: TOXCASTSource Identifier: DTXSID5025815]169.51 Ų [M+Na]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| Other Experimental Properties | SPARINGLY SOL IN WATER, SLIGHTLY SOL IN ETHANOLINSOL IN CHLOROFORM, DIETHYL ETHER & BENZENEVERY SLIGHTLY SOL IN ACETONEMP: 136 DEC C /CITRATE/ |
| Dichte | 1.0278 (rough estimate) |
| Brechungsindex | 1.5740 (estimate) |
| pKa (Säurekonstante) | pKa 8.4 (Uncertain) |
| Aggregatzustand | Solid |
| Farbe | Light yellow to brown |
| CAS Datenbank | 83-98-7 |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 39 reports by companies from 1 notifications to the ECHA C&L Inventory. |
|---|---|
| Regulatorische Informationen | REACH registered substance: Orphenadrine (EC: 201-509-2)Orphenadrine: Does not have an individual approval but may be used under an appropriate group standard |
| Weitere Sicherheitsinformationen | IMAP assessments - Ethanamine, N,N-dimethyl-2-[(2-methylphenyl)phenylmethoxy]-: Human health tier I assessment |
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
| Treatment | Treatment for orphenadrine overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring, and appropriate supportive treatment of any emergent anticholinergic effects. (L1712) |
| Wechselwirkungen | ORPHENADRINE HAS BEEN REPORTED TO ENHANCE CNS EFFECTS OF PROPOXYPHENE WHEN THESE DRUGS ARE USED CONCURRENTLY.IN MICE BOTH NEOSTIGMINE & PHYSOSTIGMINE INCREASED TOXICITY OF ORPHENADRINE. BUT ARECOLINE...PROVIDED SIGNIFICANT PROTECTION AGAINST ACUTE LETHAL EFFECTS. |
| Hepatotoxicity | Despite its long clinical use, there is no evidence of hepatotoxicity with orphenadrine. Several cases of severe orphenadrine overdose with cardio-respiratory arrest and ischemic hepatic injury have been reported. Conventional doses of orphenadrine appear to be free of hepatic injury. |
| Expositionspfade | Orphenadrine is almost completely absorbed in the gastrointestinal tract. |
| Toxizitätsübersicht | Orphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect. |
Anwendungen & Verwendung
Verwenden
Relaxant (skeletal muscle); antihistaminic.